Angiotensin II receptor antagonists in arterial hypertension

Journal of Human Hypertension

Volumn 14, Issue , 2000, Pages S69-S72

  Hernández Hernández, Rafael ^a   Velasco, M ^b   Armas Hernandez M J ^a   Armas Padilla, M C ^a  

^a UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Angiotensin II receptor antagonist; AT 1 receptor; AT 2 receptor; Losartan

Indexed keywords

2 ETHYL 4 [2' (1H TETRAZOL 5 YL)BIPHENYL 4 YLMETHOXY]QUINOLINE; 2,7 DIETHYL 5 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5H PYRAZOLO[1,5 B][1,2,4]TRIAZOLE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; FORASARTAN; IMIDAZOLE DERIVATIVE; IRBESARTAN; LOSARTAN; LRB 081; SARALASIN; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN; ZOLASARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CATECHOLAMINE RELEASE; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NONHUMAN; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 0343673399     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000990     Document Type: Article

References (33)

1. Streeten DH, Anderson GH, Dalakos TH. Angiotensin II blockade: its clinical significance. Med 1976; 60: 817-824.
2. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis 1974; 17: 87-98.
3. Furukawa Y, Kishimoto S, Hishikawa K. Takeda Chemical Industries Ltd. Hypotensive imidazole-5 acetic acid derivatives. US Patent 4 355 040, July 20, 1982.
4. Wexeler RR et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am Hyp-ertens 1992; 5: 209S-220S.
5. Chuiu AT et al. Non peptide angiotensin II receptor antagonists, VIII: characterization of functional antagonism displayed by DuP-753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
6. Gansevoort RT et al. Effects of the angiotensin II antagonists losartan in hypertensive patients with renal disease. J Hypertens 1994; 12: S37-S42.
7. de Gasparro M, Bottari S, Levens NR. Characteristics of angiotensin II receptor and their role in cell and organ physiology. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis and Management. Second edition. Raven Press Ltd, New York, 1995, pp 1695-1720.
8. Israelii ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitors therapy: a review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
9. Timmermans PBMW et al. Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 221S-234S.
10. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research. J Hypertens 1994; 12: S1-S5.
11. Sasamura H et al. Cloning, characterization and expre-sion of two antiotensin receptors (AT-1) isoforms from the mouse genome. Biochem Biophys Bes Commun 1992; 351: 253-259.
12. de Gasparo M et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25: 924-927.
13. Wong PC et al. Non-peptide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension 1990; 15: 823-834.
14. Markahm A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drug 1997; 54: 299-311.
15. Ruilope L. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist. J Hypertens 1997; 15: S15-S20.
16. Criscione L et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Bes 1995; 13: 230-250.
17. Weber MA. Comparison of type I angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors in the treatment of hypertension. J Hypertens 1997; 15 (5): S32-S36.
18. Chan JCN et al. A randomized, double blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared to felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-771.
19. Mallion JM, Goldberg AL. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press 1996; 2: 82-86.
20. Softer BA et al. Effects of losartan on a blackground of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
21. Gavras I, Gavras H. Effects of eprosartan versus enalap-ril in hypertensive patients on the rennin angiotensin-aldosterone system and safety parameters; results from a 26 week, double-blind, multicenter study. Curr Med Res Opin 1999; 15: 15-24.
22. Zanchetti A. Candesartan cilexitil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997; 11 (2): S57-S59.
23. Pouleur HG. Clinical overview of irbesartan: a new angiotensin II receptor antagonist. Am J Hypertens 1997; 10 (Suppl): 318S-324S.
24. Mallion JM et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997; 2: 179-184.
25. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
26. Cruickshank JM et al. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6: 85-90.
27. Mizuno K et al. Effects of losartan, a non-peptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51: 367-374.
28. Bunkenburg B et al. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992; 20: 746-754.
29. Thiirmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
30. Brunner HR. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10 (Suppl): 311S-317S.
31. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hyrochrolothiazide, atenolol, felodipine AR and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-795.
32. Chan P et al. Double-blind comparison of losartan, lisi-nopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37: 253-257.
33. Gradman AH et al. Assesment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension, Eprosartan Study Group. Clin Ther 1999; 21: 442-453.